These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 17922444)

  • 1. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular calcification in nondialyzed patients with chronic kidney disease.
    Qunibi WY
    Semin Dial; 2007; 20(2):134-8. PubMed ID: 17374087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL; Swan VJ; Jamal SA
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperphosphatemia and cardiovascular risk in patients on dialysis].
    Basić-Jukić N; Kes P
    Acta Med Croatica; 2004; 58(3):207-13. PubMed ID: 15503684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
    Martola L; Elinder CG; Stenvinkel P
    Lakartidningen; 2003 Dec; 100(50):4180-3. PubMed ID: 14717005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular calcification and ESRD: a hard target.
    Bhan I; Thadhani R
    Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S102-5. PubMed ID: 19995990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease.
    Raggi P; Kleerekoper M
    Clin J Am Soc Nephrol; 2008 May; 3(3):836-43. PubMed ID: 18322050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders.
    Guérin AP; Pannier B; Marchais SJ; London GM
    Curr Opin Nephrol Hypertens; 2006 Mar; 15(2):105-10. PubMed ID: 16481874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients.
    Sit D; Kadiroglu AK; Yilmaz ME; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):403-7. PubMed ID: 16060127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of secondary hyperparathyroidism in dialysis patients].
    Di Luca M
    G Ital Nefrol; 2009; 26 Suppl 49():S36-48. PubMed ID: 19941277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of extraskeletal calcifications in uremia].
    Cozzolino M; Galassi A; Bellasi A; Butti A; Zoni U; Gallieni M; Brancaccio D
    G Ital Nefrol; 2005; 22 Suppl 31():S53-5. PubMed ID: 15786403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.